Home › Niet-kleincellige longkanker › Californië › Orange
Niet-kleincellige longkanker klinische studies in Orange, CA
25 studies voor Niet-kleincellige longkanker zoeken deelnemers op locaties in en rond Orange (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
RekruterenFase 2/3
- Providence St. Joseph Hospital, Orange
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RekruterenFase 3
- University of California, Irvine Health, Orange
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
RekruterenFase 2
- University of California Irvine, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekruterenFase 3
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruterenFase 2
- St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange
- University of California Irvine, Orange
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekruterenFase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RekruterenFase 1
- University of California - Irvine, Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekruterenFase 2/3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruterenFase 1/2
- UC IRVINE Health, Orange
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruterenFase 1
- University of California Irvine Medical Center, Orange
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekruterenFase 3
- Clinical Study Site, Orange
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
RekruterenFase 3
- University of California Irvine, Orange
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
RekruterenFase 2
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekruterenFase 3
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekruterenFase 3
- Providence St. Joseph Hospital, Orange
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
RekruterenFase 3
- Research Site, Orange
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekruterenFase 1
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
RekruterenFase 1/2
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RekruterenFase 1
- Research Site, Orange
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RekruterenFase 3
- UCI Chao Family Comprehensive Cancer Center, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekruterenFase 1/2
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
RekruterenFase 1
- Research Site, Orange
A Study of VET3-TGI in Patients With Solid Tumors
RekruterenFase 1
- UC Irvine Health, Orange
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
RekruterenObservatieonderzoek
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Orange
Niet-kleincellige longkanker studies in andere steden
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Andere studies in Orange
- Metastatische kanker20 studies
- Colorectale kanker16 studies
- Eierstokkanker16 studies
- Aldermeesklierkanker15 studies
- Melanoom14 studies
- Leverkanker (hepatocellulair carcinoom)14 studies
- Borstkanker14 studies
- Longkanker14 studies
- Prostaatkanker14 studies
- Maagkanker13 studies
- Kanker (alle vormen)13 studies
- Acute myeloïde leukemie13 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.